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OBJECTIVES We postulated a change of angiotensin II receptor subtype expression in patients with lone
atrial fibrillation (AF) and AF with underlying mitral valve disease (MVD) both compared
with sinus rhythm (SR).
BACKGROUND Atrial fibrillation is a progressive disease associated with electrical and structural remodeling.
Angiotensin II (ANGII) is involved in the process of myocardial remodeling. Actions of
ANGII are mediated by ANGII receptor subtypes 1 and 2 (AT1 and AT2).
METHODS Left atrial (LA) and right atrial (RA) tissue samples were obtained from patients with AF or
SR with or without underlying MVD. The AT1 and AT2 protein levels were measured by
quantitative Western blotting techniques.
RESULTS The AT1 protein level in the LA was significantly increased in patients with AF (all forms)
compared with SR (p  0.05), whereas AT2 expression was not significantly altered.
Comparison of the subgroups revealed a similar increase of AT1 in both paroxysmal AF and
chronic AF with or without MVD. Additionally, investigations of ANGII receptor subtypes
in the RA did not exhibit any significant changes either in AT1 or in AT2 in patients with
AF versus SR. Underlying MVD did not significantly affect AT2 receptor subtype expression
in LA.
CONCLUSIONS Atrial fibrillation is associated with an up-regulation of AT1 in LA, but not in RA, and did
not appear to influence the AT2 expression in the atrium. Because we found an enhanced
expression of AT1in the LA, we conclude that AT1 might be involved in the pathogenesis of
AF in the LA. (J Am Coll Cardiol 2003;42:1785–92) © 2003 by the American College of
Cardiology Foundation
About 1% of the population is suffering from the most
common cardiac arrhythmia, atrial fibrillation (AF). Its
incidence increases with age and/or will be promoted by risk
factors such as rheumatic and ischemic heart disease, hy-
pertension, or congestive heart failure. However, AF may
also occur in the absence of cardiovascular disease (lone AF)
(1–3).
The pathophysiology of AF with electrical and structural
remodeling of the atria has been described (e.g., electrical
and structural remodeling might be responsible for an
enhanced stability of AF) (4–9). Nakashima et al. (7)
suggested that angiotensin II (ANGII) may be involved in
the process of atrial electrical remodeling. The activity of
ANGII is mediated by its receptor subtypes 1 and 2 (AT1
and AT2) (10). However, Goette et al. (11) found in right
atrial (RA) tissue of patients with AF an up-regulation of
AT2 and a down-regulation of AT1. The role of underlying
cardiac disease was not investigated in that study. However,
because fibrotic changes of the tissue are often observed in
AF and in case of an involvement of ANGII, this would be
mediated via AT1. The study of Goette et al. (11) is not easy
to fit into the pathophysiology of AF but might indicate, as
they suggest, a counter-regulation of AT1-induced fibrosis
via AT2 up-regulation. However, these authors investigated
RA tissue, while AF normally originates in and depends on
the left atrium (LA). Sources of initiation and maintenance
of AF are localized in the LA and AF propagates through
both atria (12). Therefore, we chose human tissue samples
from the LA and, for comparison, RA. Recent clinical
findings favor a promoting role of AT1 in AF (13).
Furthermore, previous studies suggest that an up-regulation
of AT1 leads to increased extracellular matrix component
production, cell growth, or vasoconstriction, whereas AT2
counter-regulates the effects of the AT1. The stimulation of
AT2 promotes antiproliferative and antigrowth effects.
Moreover, AT2 receptor stimulation attenuates the progres-
sion of myocardial fibrosis and advances antifibrotic pro-
cesses (9,14). Because AF is associated with an increased
amount of atrial fibrosis and AT1 has profibrotic effects,
which are attenuated by AT2 (15–17), we suppose an
up-regulation of AT1 and a down-regulation of AT2 in the
LA in patients with AF.
The aim of the present study was to quantify the AT1 and
AT2 expression in human LA and RA. We compared
patients with sinus rhythm (SR) and AF (paroxysmal atrial
fibrillation [PAF] and chronic atrial fibrillation [CAF])
with or without underlying mitral valve disease (MVD).
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METHODS
Patients. The study groups consisted of patients undergo-
ing cardiac surgery for lone AF (lone AF group, n  40;
PAF, n  19; CAF, n  21), for mitral valve repair or
replacement in conjunction with intraoperative radiofre-
quency ablation of AF (MVD  AF group, n  35; PAF,
n  6; CAF, n  29) and patients undergoing cardiac
surgery for coronary artery bypass grafting, aortic valve
replacement, or valve repair (Table 1) (SR group, n  15; n
 8 with coronary artery bypass grafting or aortic valve
replacement as control group for the lone AF group; n  7
with an underlying MVD). Patients in the control group
were matched to the AF groups according to age, LA size,
and left ventricular (LV) function. Patients were included in
the study only if they had preserved LV function and a LA
size of 45 mm as assessed by echocardiography for the
lone AF group. The surgical procedure and the concept of
intraoperative ablation of AF have been described in detail
previously (18). All patients gave informed consent. The
institutional ethical committee approved the study. The
investigation conforms with the principles outlined in the
Declaration of Helsinki.
Atrial tissue from all patients was obtained from the LA
free wall near the interatrial septum (about 5 to 5 mm from
atriotomy) or RA free wall near the auricle, both during
cardiac surgery, quick-freezed in liquid nitrogen, and stored
at 80°C until use.
Western blot analysis. Frozen atrial tissue was homoge-
nized in N-(2Hydroxymethyl)piperazine-N-(2ethane-
sulfonicacid) buffer with 0.5 mg/ml leupeptin, 10 g/ml
aprotinin, and 1 mM phenylmethylsolfonyl floride (Boehr-
inger, Mannheim, Germany). For electrophoresis, 20 g of
total protein from homogenized total tissue was separated in
a sodium dodecyl sulfate-polyacrylamide gel and blotted
onto polyvenylinendifloride membrane (Roth, Karlsruhe,
Germany). Rabbit–anti-human AT1 and rabbit–anti-
Abbreviations and Acronyms
AF  atrial fibrillation
ANGII  angiotensin II
ANOVA  analysis of variance
AT1  angiotensin II receptor type 1
AT2  angiotensin II receptor type 2
CAF  chronic atrial fibrillation
CHF  congestive heart failure
GAPDH  glyceralaldehyde-3-phosphate dehydrogenase
LA  left atrial/atrium
LV  left ventricular
MVD  mitral valve disease
PAF  paroxysmal atrial fibrillation
RA  right atrial/atrium
SR  sinus rhythm




(Left Atrium) Control Group
AF
(Right Atrium) Control Group
n (male/female) 40 (33/7) 35 (18/17) 15 (13/2) 5 (4/1) 5 (4/1)
PAF (male/female) 19 (15/4) 6 (4/2) — 4 (4/0) —
CAF (male/female) 21 (18/3) 29 (14/15) — 1 (0/1) —
Cardiac surgery IRAAF MVR  IRAAF MVR (6) MVR (1) CABG (2)
MVR  CABG (1) CABG (2) AVR (2)
CABG (6) AVR (1) AVR  CABG (1)
AVR  CABG (2) AVR  CABG  AAR (1)
Age (yrs) (total) 52  12 65  8 59  7 68  7 68  3
PAF/CAF 50  15/54  9 63  10/65  8
LVEF (%) (total) 60  7 57  6 57  9 62  12 65  7
PAF/CAF 60  8/61  6 60  15/57  16
Left atrium (mm) (total) 43  6 55  11 42  5 50  8 38  6
PAF/CAF 43  8/44  4 53  8/56  12
Duration of AF (months) 70  60 37  43 — n.a. —
PAF/CAF 96  70/48  41 50  36/35  45
n.a.: 3 patients n.a.: 2 patients
Calcium antagonists (total) 6 (15%) 6 (17%) 3 (20%) — 1 (20%)
(PAF/CAF) (2/4) 0/6
Digitalis (total) 10 (25%) 24 (69%) 1 (7%) — —
(PAF/CAF) (3/7) (3/21)
Beta-blocker (total) 32 (80%) 25 (71%) 11 (73%) 5 (100%) 3 (60%)
(PAF/CAF) (16/16) (5/20)
Antiarrythmic drugs (total) 16 (40%) 3 (9%) — 2 (40%) —
(PAF/CAF) (10/6) (1/2)
ACE inhibitors (total) 20 (50%) 22 (63%) 8 (53%) 4 (80%) 3 (60%)
(PAF/CAF) (9/11) (4/18)
Spironolactone (total) — 3 (9%) 1 (7%) — —
(PAF/CAF) (0/3)
AAR  aortic ascendence replacement; ACE  angiotensin-converting enzyme; AF  atrial fibrillation; AVR  aortic valve replacement; CABG  coronary artery bypass
grafting; CAF  chronic atrial fibrillation; IRAAF  intraoperative radiofrequency ablation of atrial fibrillation; LVEF  left ventricular ejection fraction; MVD  mitral valve
disease; MVR  mitral valve repair or replacement; n.a.  not available; PAF  paroxysmal atrial fibrillation.
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human AT2 (Santa Cruz Biotechnology, Santa Cruz, Cal-
ifornia) were used as primary antibodies. As reference, we
used glyceralaldehyde-3-phosphate dehydrogenase
(GAPDH) detected by mouse–anti-human GAPDH
(Hytest, Turku, Finland). After washing, membranes were
incubated with secondary antibodies using goat–anti-rabbit
IgG (Dianova, Hamburg, Germany) for ANGII receptors
signals and rabbit–anti-mouse IgG for GAPDH signals
(Sigma, Deisenhofen, Germany), both conjugated with
horseradish peroxidase and subsequently developed with
Super Signal Reagent (Pierce, Rockford, Illinois).
Immunohistology. Formalin fixed, paraffin-embedded
atrial tissue sections (5-m thick) were incubated with
primary antibodies, as specified in the preceding text,
against human AT1 and AT2 receptor (dilution 1:50).
Goat–anti-rabbit IgG conjugated with horseradish peroxi-
dase (1:500) (Dianova) was used as a secondary antibody.
After washing, atrial tissue sections were incubated with
biotinylated tyramid (1:50) (Perkin Elmer, Boston, Massa-
chusetts), and subsequently incubated with streptavidin-
horseradish peroxidase (1:100) (Perkin Elmer). Finally, the
sections were developed using 3-amino-9-ethylcarbazoleas
substrate for peroxidase. The specificity of the detected
signals was controlled by omitting the primary antibodies.
Densitometric analysis. Immunoblots were exposed to
X-ray film (Eastman Kodak Co., Rochester, New York),
developed, and analyzed by ONE-Dscan 1.0 Software
(Scanalytics, Los Angeles, California). The relative amount
of ANGII receptors in each sample was investigated by
comparison of gray scale value of target proteins with the
gray scale signal of GAPDH. The GAPDH value was used
as an adjusting factor to assure that the same amount of
cellular proteins in each patient was determined. The ratio
of ANGII receptors/GAPDH from each patient was used
to calculate possible differences in ANGII receptors synthe-
sis between the patients.
Statistics. All data are represented as mean  standard
error of mean. Statistical evaluation was performed by using
Mann-Whitney test (two groups) or one-way analysis of
variance (ANOVA) with subsequent post-hoc Tukey-HSD
(for three or more groups). Values of p  0.05 were
considered statistically significant. As described in the
preceding text, all data are specified as ratios (ANGII
receptors/GAPDH) and, therefore, did not require any
units.
RESULTS
Patients. Clinical characteristics of the patient population
are summarized in Table 1.
LA. Patients in the lone AF group were significantly
younger compared with all SR patients (p  0,05). Fur-
thermore, both patients in the lone AF group and in the SR
group were significantly younger than patients in the MVD
 AF group (p  0.05). The LA sizes in both the lone AF
and the SR group were significantly lower than in the MVD
 AF group (p  0.05), while there was no difference
between lone AF and SR. There were no significant
differences in the LV ejection fraction between lone AF,
MVD  AF, and SR groups.
RA. There were no significant differences, except patients in
SR had a slightly lower LA size than patients in AF (p 
0.055), while RA size was normal in both groups.
Histological results. Immunhistochemical staining for
AT1 and AT2 receptors of LA tissue of patients in SR
compared with patients in AF showed clear differences;
there was a higher presence of AT1 in patients in AF (all
forms) (Fig. 1B) compared with patients in SR (Fig. 1A).
Expression of AT2 was unaltered in patients in AF (Fig.
1D) compared with patients in SR (Fig. 1C). After detect-
ing clear histological differences in the LA tissue between
patients in SR and patients in AF, the differences were
quantified by Western blot techniques.
ANGII receptor expression in LA/RA. Western blot
analysis in the LA revealed an increase of AT1 in patients
with AF (all AF) compared with patients in SR (all SR)
control group. The protein expression of AT1 (1.46  0.13;
n  74) was significantly (about two-fold) increased com-
pared with the SR control group (0.60  0.10; n  14; p 
0.001). In contrast, in the LA, the protein expression of
AT2 exhibited no significant changes under influence of AF
(1.45  0.11; n  74) compared with the SR control group
(1.71  0.27; n  13) (Figs. 2 and 3A). The ratio of
AT1/AT2 was significantly enhanced (about five-fold; p 
0.0001) in patients in AF (1.41  0.15; n  74) compared
with patients in SR (0.32  0.06; n  14) (Fig. 3A).
Analysis of AT1 and AT2 expression in the RA tissue
revealed no significant changes between patients in SR (n
5) and AF (n  5) (Fig. 3B). However, there was a slight,
but not significant, increase in AT2 expression in the RA
(p  0.09).
Influence of MVD on ANGII receptor expression in the
LA. Next we analyzed the influence of MVD on the AT1
and AT2 expression. Comparing all patients without MVD
(SR and lone AF) with patients with underlying MVD
(SRMVD and all MVD AF), we could not detect any
significant changes between both groups either in AT1
(1.41  0.17; n  48 vs. 1.33  0.18; n  41) or in AT2
(1.53  0.14; n  45 vs. 1.44  0.15; n  42). Further-
more, the ratio AT1/AT2 did not exhibit any significant
changes between patients with (1.30  0.19; n  42) and
without underlying MVD (1.21  0.18; n  48) (Fig. 4A).
Differences between SR, lone AF, and MVD  AF in
LA. Using the ANOVA, significant changes in AT1 ex-
pression among SR, lone AF, and MVD  AF were
detected (p  0.02). Patients in lone AF exhibited an
increase in AT1 expression (1.48  0.18; n  39; p  0.05)
compared with the SR control group (0.60 0.10; n 14).
Likewise, there was also a considerable increase in patients
with MVD  AF (1.43  0.17; n  35; p  0.05) in
comparison with the SR control group (Fig. 4B). In
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contrast, there were no significant changes in AT2 receptor
expression (Fig. 4C). Exemplary Western blots are shown in
Figure 2.
Considering the ratio AT1/AT2, there were significant
changes comparing SR versus lone AF and MVD  AF
using ANOVA (p  0.001). The change of the ratio
AT1/AT2 in the lone AF group (1.41  0.21; n  39; p 
0.05) was almost as high as in the MVD  AF group (1.41
 0.22; n  35; p  0.05) (vs. SR [0.32  0.07; n  14]),
(Fig. 4D).
Influence of PAF and CAF in LA. To investigate the
influence of PAF and CAF, the AT2 expression in patients
with lone PAF and lone CAF, MVD PAF, and MVD
CAF, and patients in SR were compared.
Using ANOVA we could not detect any significant
changes between PAF and CAF either in AT1 expression or
in AT2 expression (Fig. 5).
The ratio AT1/AT2, however, was significantly changed
in both lone PAF (1.63  0.35; n  19; p  0.001) and
lone CAF (1.22  0.21; n  21; p  0.01) versus SR
control group (0.18  0.03; n  8). Other differences
among the subgroups did not reach the level of statistical
significance (Fig. 5C).
DISCUSSION
The present study demonstrates a clear relationship between
AT1 up-regulation and AF in the LA. We were able to find
an increase of about 100% in AT1 expression in LA tissue of
patients in AF (both lone AF and MVD  AF) compared
with patients in SR. Interestingly, AF does not appear to be
associated with the regulation of the AT2 in human LA.
Thus, our data seem to confirm an association between AF
and (AT1-mediated) actions of ANGII in both lone AF and
MVD  AF.
Previous studies reported about the relationship of ac-
tions of ANGII and (other) cellular components that are
involved in electrical and structural remodeling in AF such
as, for example, connexin 43. Shyu et al. (19) and Polont-
chouk et al. (20) observed an increase of connexin 43
mediated by activation of AT1 in cultured rat cardiomyo-
cytes. Additionally, Emdad et al. (21) described an impor-
tant role of AT1 in gap-junctional remodeling. Moreover,
Elvan et al. (22) observed an increased expression and
changed distribution of connexin 43 in dogs with CAF,
which became reduced by intraoperative radiofrequency
ablation, whereas in a similar goat model of persistent AF,
the expression of connexin 43 remained unchanged (23,24).
These studies might indirectly indicate a possible role of
Figure 1. Immunostaining of angiotensin II (ANGII) receptors. Exemplary pictures of immunostaining of ANGII subtypes in human left atrial tissue.
(A, B) Antibodies against human AT1 (red-stained pixels) in sinus rhythm (SR) (A) and lone chronic atrial fibrillation (CAF) (B) were used for
immunostaining in paraffin-embedded tissue sections. (C, D) Antibodies against human AT2 (red-stained pixels) were used for immunostaining of
paraffin-embedded tissue sections of patients with SR (C) and lone CAF (D).
Figure 2. Exemplary Western blots for human AT1 (A) and AT2 (B)
expression in atrial fibrillation (AF). (A) A specific band at 52 kDa for AT1
is detected in left atrial tissue of patients in sinus rhythm (SR), lone chronic
atrial fibrillation (CAF), and patients with CAF and underlying mitral
valve disease (MVD). (B) Western blots for AT2 with a specific band at 52
kDa were performed for patients with SR, lone CAF, and MVD  CAF.
Monoclonal antibodies for human glyceralaldehyde-3-phosphate dehydro-
genase (GAPDH) with a specific band at 36 kDA were used as reference.
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AT1 and angiotensin in the remodeling process in AF.
Attributes of structural remodeling such as fibroblast and
myocyte cell growth or the promotion of extracellular matrix
component (e.g., collagen type 1, fibronectin) synthesis
could be mediated by AT1 (14,25–27). AT1, as a promotor
of extracellular matrix component synthesis, and the knowl-
edge of an enhanced fibrosis in tissue with AF might
indicate a possible role of AT1 in structural remodeling in
AF (3,17,28).
However, Goette et al. (11) showed an up-regulation of
AT2 and a down-regulation of AT1 in the human RA in 19
patients with AF versus 11 patients with SR. We also found
some slight up-regulation of AT2 in the RA. The difference
in the changes in the LA with enhanced AT1 and un-
changed AT2 might be caused by the fact that the RA is not
the source of genesis of AF, but the LA (29). The increase
in AT1 (in LA) might be related to increased fibrosis in AF,
because it is known that ANGII mediates its growth-
promoting effects via AT1 (3,16,28). Both Goette et al. (11)
and we interpret the increase in AT2 in the RA in AF
(which did not reach significant levels in our study probably
due to the smaller number of RA) as a counter-regulation
against ANGII-AT1-induced fibrosis in AF.
Because AF pathophysiologically depends on the LA, it
seems important to investigate LA (29). In fact, from our
data we believe that ANGII is associated with AF and that
changes in the expression of AT1 might contribute to the
remodeling process and stabilization of AF with time. This
is supported by a recent clinical trial, showing that addi-
tional treatment with the AT1 antagonist irbesartan in
combination with amiodarone reduced the rate of recur-
rence of AF more than treatment with amiodarone alone
(13).
Furthermore, a previous study indicated that ANGII
plays an important role in congestive heart failure (CHF)-
induced atrial enlargement with atrial remodeling and atrial
fibrosis, which can make the atrium more susceptible to AF
(26). In this study, the action of ANGII was blocked with
the angiotensin-converting enzyme inhibitor enalapril, re-
sulting in a significantly reduced atrial fibrosis during
CHF-induced atrial enlargement. In a similar dog model,
Li et al. (30) investigated CHF-induced atrial remodeling
(CHF by tachypacing) and found in the LA increased AT1
and AT2 expression as well as increased fibrosis in CHF,
which induced susceptibility to pacing-induced AF. Atrial
fibrosis-increased AT1 (and, in parts, AT2) expression could
be inhibited by enalapril, indicating a pathophysiologic role
for ANGII in CHF-induced atrial remodeling. However,
we did not observe an effect of MVD on AT1 expression,
which might be related to the different models
(tachypacing-induced CHF with atrial enlargement in dogs
vs. MVD in humans). On the other hand, the papers by Shi
et al. (26) and Li et al. (30) also indicate in principle a role
for AT1 in a process leading to enhanced atrial susceptibility
for AF in LA tissue, which seems to be in accordance with
our findings.
Other authors found that immediate early gene, late
genes, and growth factors (e.g., transforming growth factor
beta-1 gene) were completely blocked by an AT1 receptor
antagonist and not by AT2 receptor antagonist (31). Otsuka
et al. (32) showed that increased collagen I and aortic
hydroxyproline concentration were prevented by inhibition
of AT1 and not by inhibition of AT2. Accordingly, these
data and our results suggest that AF is associated with an
overexpression of AT1 simultaneously with an increase in
fibrosis in cardiac tissue. Furthermore, AT2 did not appear
to be involved in this remodeling process in AF. However,
according to Goette et al. (11), it might be that in certain
circumstances there is counter-regulation of AT1-induced
process by up-regulation of AT2 in AF.
In fact, the up-regulation of AT1 as shown in our study
may influence the enhanced synthesis of fibrotic factors
Figure 3. Basic differences in AT1 and AT2 expression and ratio of
AT1/AT2 in (A)/(B) atrial tissue of patients in sinus rhythm (SR) versus
atrial fibrillation (AF); (A) Comparison of left atrial tissue of patients in SR
(left columns) and AF (right columns). (B) Comparison of right atrial
tissue of patients in SR (left columns) and AF (right columns). GAPDH
 glyceralaldehyde-3-phosphate dehydrogenase.
1789JACC Vol. 42, No. 10, 2003 Boldt et al.
November 19, 2003:1785–92 Angiotensin in Arrhythmia
(e.g., collagen type 1 and fibronectin) and increased con-
nexin 43 expression. Accordingly, actions of ANGII, me-
diated by AT1, might play a role in structural and electrical
remodeling in AF. The finding that AT1 was only up-
regulated in LA may indicate a pathophysiologic role for
ANGII in AF.
Conforming with previous studies, we could detect a
larger LA diameter in patients with MVD  AF compared
with patients with SR and patients with lone AF (Table 1)
(33,34). However, patients with underlying MVD (MVD
 AF and MVD  SR) did not exhibit any significant
changes either in AT1 or in AT2 expression compared with
patients without underlying MVD (lone AF and SR).
Furthermore, lone AF and MVD  AF exhibited a similar
increase in AT1 expression compared with SR. The AT2
expression among SR, lone AF, and MVD  AF remained
unchanged. Additionally, both SR and MVD  SR exhib-
ited similar low AT1 expression compared with lone PAF,
lone CAF, MVD  PAF, or MVD  CAF (Fig. 4A).
Thus, we assume that an up-regulation of AT1 was not
associated with MVD. Supporting our suggestion, Schotten
et al. (28) observed that the differences in extracellular
matrix synthesis between patients in SR compared with
those in AF were similar to patients with MVD.
It is known that systematic differences between PAF and
CAF exist. Thus, patients with CAF exhibit a shorter cycle
length and a higher degree of disorganized activity com-
pared with patients with PAF (35,36). However, we could
not confirm a systematic progressive up-regulation of AT1
or down-regulation of AT2 from PAF to CAF either in the
lone AF group or in MVD  AF group. This is supported
by other studies, which also could not find differences
between PAF and CAF in human AF of different causes
(e.g., AF with MVD, coronary artery disease, and lone AF)
regarding angiotensin or other pathophysiologic factors
such as endothelin (11,37).
Figure 4. Influence of mitral valve disease (MVD) on angiotensin II receptor expression. (A) Expression of AT1 and AT2 and ratio AT1/AT2 in left atrial
tissue of patients with MVD (sinus rhythm [SR] and atrial fibrillation [AF], left columns) and without MVD (SR and AF, right columns). (B) AT1 and
(C) AT2 expression and ratio of AT1/AT2 (D) in left atrial tissue of patients in SR, lone AF, and AF with underlying MVD. GAPDH 
glyceralaldehyde-3-phosphate dehydrogenase.
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To the best of our knowledge, this is the first study that
determined the regulation of AT1 and AT2 in the human
LA in patients suffering from AF. Furthermore, we consid-
ered the separate subgroups, both PAF and CAF, with or
without an underlying MVD.
In conclusion, AF is associated with an up-regulation of
AT1 in human LA (but not RA) tissue and did not
influence the expression of AT2. However, there was no
systematic difference in ANGII receptor subtype expression
between PAF and CAF. Mitral valve disease in combina-
tion with AF has no influence on AT1 expression and was
not associated with a change in AT2 expression. Because AF
normally originates from LA, our finding that AT1 expres-
sion was only enhanced in LA, but not in RA, tissue can
only cause speculation that this may indicate a possible
pathophysiologic role for ANGII and AT1 in AF.
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